ATRA
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Atara Biotherapeutics reports FDA acceptance of the resubmitted biologics license application for tabelecleucel (Tab-cel)Oct 14, 2026
- Pierre Fabre Pharmaceuticals announces transfer from Atara Biotherapeutics of the biologics license application for Tabelecleucel as treatment of Epstein-Barr virus positive post-transplant lymphoproliferative diseaseNov 3, 2025
- Atara Biotherapeutics announces FDA acceptance and priority review of BLA for Tabelecleucel (Tab-cel®) to treat EBV+ PTLDJul 24, 2025
- Perre Fabre Pharmaceuticals announces transfer of investigational new drug application for Tabelecleucel from Atara BiotherapeuticsJul 15, 2025
- Atara Biotherapeutics provides regulatory and business updates on Tabelecleucel (Tab-cel®)Jul 14, 2025